Email This Release
Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire